pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Updates
The latest update as of May 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows:
- Nine new drug products have initiated pCPA negotiations since the last update, for a total of 43 active negotiations
- Four negotiations have been completed since the last update, for a total of 153 joint negotiations.
- No new drug products were added to the “No pCPA Negotiations” list
- Five new drug products have received recent CDEC or pERC recommendations since the last update, for a total of approximately 25 products under pCPA Consideration
Please see below for more details.
- Nine new drug products have initiated pCPA negotiations since the last update, for a total of 43 active negotiations
- Brivlera (brivaracetam; UCB Canada Inc.) – partial-onset seizures
- Butrans (buprenorphine; Purdue Pharma) – persistent pain of moderate intensity
- Ibrance (palbociclib; Pfizer Canada Inc.) – advanced breast cancer
- Invega Trinza (paliperidone palmitate; Janssen-Ortho Inc.) – schizophrenia
- Invokamet (canagliflozin/metformin hydrochloride; Janssen Inc.) – type 2 diabetes mellitus
- Kuvan (sapropterin dihydrochloride; BioMarin Pharmaceutical (Canada) Inc.) – Phenylketonuria (PKU)
- Mifegymiso (mifepristone/misoprostol; Celopharma Inc.) – medical termination of pregnancy
- Quinsair (levofloxacin; Raptor Pharmaceuticals Inc.) – cystic fibrosis with chronic Pseudomonas aeruginosa infections
- Taltz (ixekizumab; Eli Lilly Canada Inc.) – moderate to severe plaque psoriasis
- Four negotiations have been completed since the last update, for a total of 153 joint negotiations.
- Cotellic (cobimetinib; Hoffman-la Roche Ltd.) – metastatic melanoma
- Humira (adalimumab; AbbVie Corporation) – ulcerative colitis
- Rituxan SC (rituximab; Hoffman-la Roche Ltd.) – multiple indications
- Vectibix (panitumumab; Amgen Canada Inc.) – metastatic colorectal cancer
- No new drug products were added to the “No pCPA Negotiations” list
- Five new drug products have received recent CDEC or pERC recommendations since the last update, for a total of approximately 25 products under pCPA Consideration
- Alecensaro (alectinib; Hoffman-la Roche Ltd.) – non-small cell lung cancer (with CNS metastases)
- Tagrisso (osimertinib; Astra Zeneca Canada Inc) – non-small cell lung cancer
- Lancora (ivabradine; Servier Canada Inc.) – Heart failure, NYHA class II or III
- Lixiana VTE (edoxaban; Daiichi Sankyo, Inc.) – venous thromboembolism, treatment and recurrence prevention
- Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide; Gilead Sciences Canada, Inc.) – HIV-1 Infection
The other 20 products under consideration are as follows:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Final Recommendation/
|
|---|---|---|---|---|
Naglazyme |
Galsulfase | BioMarin Pharmaceutical (Canada) Inc. | Mucopolysaccharidosis VI | 19-Feb-16 |
Trulicity |
Dulaglutide | Eli Lilly Canada Inc. | Diabetes mellitus, Type 2 | 16-Jun-16 |
Revestive |
Teduglutide | Shire Pharma Canada ULC/NPS Pharma Holdings Limited | Short Bowel Syndrome (SBS) | 27-Jul-16 |
Descovy |
Emtricitabine /tenofovir alafenamide | Gilead Sciences Canada, Inc. | HIV-1 infection | 24-Aug-16 |
Truvada |
Emtricitabine/tenofovir disoproxil fumarate | Gilead Sciences Canada, Inc. | HIV-1 infection, pre-exposure prophylaxis | 24-Aug-16 |
Brilinta |
ticagrelor | AstraZeneca Canada Inc | Prevention of atherothrombotic events with history of myocardial infarction | 25-Aug-16 |
Synjardy |
Empagliflozin and metformin | Boehringer Ingelheim (Canada) | Diabetes mellitus (Type 2) | 25-Oct-16 |
Otezla |
Apremilast | Celgene | Psoriasis, moderate to severe plaque | 26-Oct-16 |
Viacoram |
perindopril arginine / amlodipine | Servier Canada Inc. | Hypertension, essential | 26-Oct-16 |
Hemangiol |
Propranolol oral solution | Pierre Fabre Dermo-Cosmétique | Infantile hemangioma | 21-Feb-17 |
Lixiana NVAF |
Edoxaban | Daiichi Sankyo, Inc | Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism | 21-Mar-17 |
Stelara |
ustekinumab | Janssen Inc. | Crohn’s disease | 21-Mar-17 |
Actikerall |
Fluorouracil and Salicylic Acid | Cipher Pharmaceuticals Inc. | Hyperkeratotic actinic keratosis | 22-Mar-17 |
Cinqair |
Reslizumab | TEVA Canada Innovation | Asthma, eosinophilic | 22-Mar-17 |
Cortiment |
Budesonide | Ferring Inc. | Ulcerative Colitis | 22-Mar-17 |
Zykadia |
Ceritinib | Novartis Pharmaceuticals Canada | Non-Small Cell Lung Cancer | 05-Apr-17 |
Caprelsa |
Vandetanib | Sanofi Genzyme | Medullary Thyroid Cancer | 17-Apr-17 |
Kyprolis |
Carfilzomib | Amgen Canada Inc. | Multiple Myeloma (relapsed) | 17-Apr-17 |
Kevzara |
sarilumab | Sanofi Genzyme | Arthritis, Rheumatoid | 18-Apr-17 |
Mictoryl |
Propiverine hydrochloride | Duchesnay Inc. | Overactive bladder (OAB) | 19-Apr-17 |
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
